Discovery of BBI-355, a Potent, Selective, and Orally Available Checkpoint Kinase 1 Inhibitor for the Treatment of Extrachromosomal DNA Oncogene-Amplified Cancers
Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 17814-17824
DOI: 10.1021/acs.jmedchem.6c00822 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 15.07.2026. Verfasst von S Todd Meyer und 16 weiteren Autor:innen. Beteiligte Einrichtung: Boundless Bio, Inc, 10955 Alexandria Way Suite 100, San Diego, California92121, United States. Hauptthemen laut MEDLINE: Checkpoint Kinase 1, Protein Kinase Inhibitors, Antineoplastic Agents, Neoplasms. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
Checkpoint kinase 1 (CHK1), a master regulator of replication stress, has been investigated as a potential therapeutic target for over two decades. More recently, CHK1 has been implicated as a target for the treatment of ecDNA-driven, oncogene-amplified cancers. However, clinical-stage CHK1 inhibitors have historically faced challenges related to dosing schedule, tolerability, and clinical efficacy, although recent studies suggest that biomarker-driven approaches and alternative dosing strategies may address some of these limitations. Structure-guided optimization led to the discovery of BBI-355, a potent, selective, and orally available CHK1 inhibitor. BBI-355 demonstrates strong antitumor activity when dosed orally in mouse xenograft models, achieving regressions both as a single agent and in combination with targeted therapies. BBI-355 also displays favorable ADMET and PK properties and has been advanced to a clinical trial for patients with oncogene amplified cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Boundless Bio, Inc, 10955 Alexandria Way Suite 100, San Diego, California92121, United States.
ORCID-Profile: S Todd Meyer, Anthony B Pinkerton
Zitieren
APA
Meyer, S. T., Chowdhry, S., Elsdon, R. J., Mauger, J., Truong, Y. P. H., Hansen, R., Plum, J., Steffy, A., Pferdekamper, A., Norman, B., Garcia, S., Tse, E., Apuy, J., Ardeshiri, A., Kasibhatla, S., Hassig, C. A., & Pinkerton, A. B. (2026). Discovery of BBI-355, a Potent, Selective, and Orally Available Checkpoint Kinase 1 Inhibitor for the Treatment of Extrachromosomal DNA Oncogene-Amplified Cancers. Journal of Medicinal Chemistry, 69(15), 17814-17824. https://doi.org/10.1021/acs.jmedchem.6c00822
Vancouver
Meyer ST, Chowdhry S, Elsdon RJ, Mauger J, Truong YPH, Hansen R, et al. Discovery of BBI-355, a Potent, Selective, and Orally Available Checkpoint Kinase 1 Inhibitor for the Treatment of Extrachromosomal DNA Oncogene-Amplified Cancers. Journal of Medicinal Chemistry. 2026;69(15):17814-17824. doi:10.1021/acs.jmedchem.6c00822
BibTeX
@article{Meyer2026,
author = {Meyer, S Todd and Chowdhry, Sudhir and Elsdon, Rachelle J and Mauger, Jacques and Truong, Yen P H and Hansen, Ryan and Plum, Joshua and Steffy, Auzon and Pferdekamper, AnneMarie and Norman, Benjamin and Garcia, Salvador and Tse, Edison and Apuy, Julius and Ardeshiri, Ardalan and Kasibhatla, Shailaja and Hassig, Christian A and Pinkerton, Anthony B},
title = {Discovery of BBI-355, a Potent, Selective, and Orally Available Checkpoint Kinase 1 Inhibitor for the Treatment of Extrachromosomal DNA Oncogene-Amplified Cancers},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {15},
pages = {17814--17824},
doi = {10.1021/acs.jmedchem.6c00822}
}
EUVIMED